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Abstract
Wound healing is a complex natural process that involves the recruitment 
of cells, the renewal of tissue composition, and the reinforcement of structural 
tissue architecture. Following ischemic injury or chronic disease, wound healing 
is delayed, and can often result in chronic inflammation or permanent morbidity. 
Tissue engineering strategies to harness the wound healing process include the use 
of naturally derived extracellular matrix (ECM) scaffolds with inherent bioactivity 
to both passively facilitate and actively direct healing toward a successful resolu-
tion. As the body heals, the properly designed ECM scaffold is gradually remod-
eled and integrated into the body, leaving behind organized tissue that provides 
long-term strength. Herein we explain the interplay of the ECM (i.e., its complex 
composition and bioactivity) with the cells of the body throughout the process of 
tissue remodeling, thus explaining how even a tissue-engineered xenograft material 
can direct the body to restore itself.
Keywords: wound healing, extracellular matrix, bioactivity, tissue remodeling, 
xenograft
1. Introduction: extracellular matrix as an implantable graft material
Biologic materials used to repair soft tissue defects must be strong and easy to 
handle during implantation, but they must also be able to support tissue integration 
and maturation once implanted. ECM-based biologic grafts have been widely used 
in surgery over the last two decades. They are a good choice for surgeons because 
they can be safely implanted in contaminated settings where synthetic materials 
are contraindicated. Even though synthetic mesh materials continue to be favored 
in general surgical practice because of their versatility and low cost, they remain 
susceptible to chemical degradation over time, can create physical tissue erosion due 
to mismatches in their mechanical properties with the surrounding tissues, and may 
undergo encapsulation following placement because the body views them as foreign 
materials [1]. Of critical importance in many applications, synthetics can provide 
a nidus for microorganism growth; therefore, if they become infected when in the 
body, they typically need to be removed [2].
ECM biomaterials derived from natural tissue sources, however, have gener-
ally provided adequate strength, resistance to infection, and stability over time 
such that they make adequate materials for soft tissue reconstruction [3].  
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These materials can be obtained as autografts or allografts, but autografts result 
in donor site morbidity, while cadaveric allograft tissues may transmit disease, 
are inherently inconsistent, and are typically quite expensive.
Recent years have seen the advent of multiple off-the shelf tissue-based ECM 
biomaterials that claim to provide an optimal healing environment for soft tis-
sues. They can be obtained from a wide variety of mammalian tissues, processed 
using a wide range of chemicals and cross-linking agents, or can be provided 
in such a way that retains the information-rich scaffold into which adjacent 
cells migrate to create a replacement tissue (Table 1). Many studies have shown 
constructive, functional tissue remodeling with partial restoration of site-
appropriate tissue using these graft materials [4–7], yet this is not always the case. 
Less favorable outcomes include the accumulation of serous fluid at the implant 
site, rapid degradation of the graft material with associated mechanical failure, 
or a lack of biomaterial integration with the patient’s tissues, resulting in a foreign 
body response [8, 9]. These less-than-favorable outcomes typically have been 
associated with variations in manufacturing methods that result in the failure 
of the material to maintain nature’s natural composition and three-dimensional 
architecture that makes the extracellular matrix (ECM) the ideal template for 
tissue repair and regeneration.
Materials that are minimally processed most closely recapitulate the structure 
and function of the original tissue while providing a safe, biocompatible material 
for soft tissue reconstruction. The natural ECM, when retained in its complex 
arrangement of matrix proteins and associated factors, can provide the key extra-
cellular signals and inherent bioactivity needed to restore damaged tissues to their 
natural state [7]. This complexity allows the naturally occurring biologic graft to 
completely integrate with the recipient’s tissues and cells to ultimately form a vascu-
larized, highly organized tissue structure that resembles the native tissue structure 
and architecture [4, 7, 10, 11].
Product Source Crosslinking agent Sterilization
Alloderm Human dermis N/A N/A
AlloMax Human dermis N/A Gamma radiation
Biodesign Porcine small intestine N/A EtO
Gentrix Porcine urinary bladder N/A E-beam
GraftJacket Human dermis N/A N/A
Meso BioMatrix Porcine mesothelium N/A EtO
MicroMatrix Porcine urinary bladder N/A E-beam
Miroderm Porcine liver N/A E-beam
OASIS Porcine small intestine N/A EtO
Peri-Guard Bovine pericardium Glutaraldehyde Liquid chemical
Permacol Porcine dermis HMDI Gamma radiation
Strattice Porcine dermis N/A E-beam
Tutoplast Human pericardium N/A Gamma radiation
XenMatrix Porcine dermis N/A E-beam
EtO ethylene oxide, E-beam Electron beam irradiation, HMDI hexamethylene diisocyanate.
Table 1. 
Source tissue and post-decellularization processing steps of some common commercially available ECM 
biomaterials.
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2. Extracellular matrix as bioactive structure
The ECM is a three-dimensional network of extracellular macromolecules, such 
as collagens, glycoproteins, proteoglycans, and glycosaminoglycans, that provides 
structural and biochemical support to surrounding cells. Because of different 
structural and mechanical requirements, the composition of ECM varies from 
tissue to tissue; however, providing a structure for cell adhesion, directing cell-to-
cell communication, and regulating cell processes such as growth, migration and 
differentiation are common functions of the ECM [12].
Regardless of the source, ECM is a complex three-dimensional scaffold consist-
ing of structural and functional proteins and components arranged in a tissue-
specific orientation [12]. The ECM components directly interact with fibroblasts, 
endothelial cells, and macrophages to maintain a natural and functional homeo-
static environment through a process known as dynamic reciprocity (Figure 1) [13]. 
When injury occurs and the natural equilibrium is disrupted, the dynamic envi-
ronment that exists between the ECM and cells orchestrates acute inflammation, 
wound healing and tissue remodeling to regain function and restore homeostasis. 
After injury occurs and the ECM is damaged, a biologic graft can be implanted 
to provide a surrogate matrix structure that allows dynamic reciprocity to begin 
immediately, ultimately achieving tissue restoration via the process of constructive 
tissue remodeling.
Endogenous ECM functions as the intended bioactive structure when normal 
tissue turnover is taking place or when no significant tissue loss is encountered. The 
body has a remarkable ability to self-renew, in large part due to the instructional 
Figure 1. 
Examples of dynamic reciprocity of fibroblasts, macrophages, endothelial cells (angiogenesis), and the 
extracellular matrix (ECM) during wound healing. These interactions occur through signals such as growth 
factors and/or binding of cells to the ECM.
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nature of the ECM, but in the presence of significant tissue loss, large areas of 
trauma, or surgical reconstructions, there is a need for an exogenous material to 
augment and to bring order to somewhat chaotic processes. An exogenous ECM can 
serve as this bioactive, instructive, and even mechanical blueprint for a constructive 
tissue remodeling process [7, 14, 15].
3. Extracellular matrix and constructive tissue remodeling
Constructive tissue remodeling is more than just another word for wound 
healing or for tissue repair. The stages of wound healing include initial hemostasis, 
characterized by clot formation; inflammation, characterized by the deposition of 
inflammatory and progenitor cells, leading to the formation of granulation tissue; 
proliferation, where resident cells secrete growth factors and cytokines and collagen 
deposition occurs; and remodeling, where the newly formed tissue matures and 
collagen strength increases to meet the demands of the body [16] (Figure 2). Tissue 
repair results in the formation of scar tissue, which is known to be less strong than 
native tissue and can therefore be more susceptible to reinjury [5].
Unlike the tissue repair process that occurs in the absence of a biologic graft 
material, the constructive tissue remodeling process that can be directed by 
an ECM graft leads to a more natural healing process in the recipient that is 
characterized by the deposition of organized connective tissue, rather than just 
chaotic scar [17]. The ideal ECM graft is characterized by an open matrix struc-
ture to allow for rapid cellular ingrowth. It is also characterized by the presence 
of structural collagens and non-collagen ECM components (such as messenger 
nucleic acids, growth factors, glycoproteins, proteoglycans, and glycosamino-
glycans), which act to facilitate the renewal of natural dynamic reciprocity [18]. 
When tissue homeostasis is disrupted, the biologic graft plays the role of the 
recipient’s natural ECM and works to bridge the recipient’s cells across the wound 
to ultimately restore a homeostatic environment. The restoration of homeostasis 
following injury in the presence of a biologic graft occurs through the constructive 
process of tissue remodeling.
Tissue remodeling is a process of tissue restoration that improves upon the scar 
tissue outcome typically achieved by tissue repair. It can be divided into three sepa-
rate phases: 1) Cell recruitment; 2) Tissue renewal; and 3) Tissue reinforcement.
During cell recruitment, the remodeling process starts when the body’s inflam-
matory and progenitor cells populate the biologic graft and release cytokines and 
growth factors that bind to the graft and recruit collagen-secreting fibroblasts 
[18, 19]. In this phase, the graft primarily acts as a scaffold material to support the 
population of the open ECM structure by the patient’s own cells.
As remodeling progresses, the patient’s macrophages and fibroblasts in the 
newly populated matrix work together with matrix-bound signaling factors to 
renew the tissue through the complementary processes of phagocytosis, collagen 
deposition, and angiogenesis. In this phase, the biologic graft is gradually replaced 
by the patient’s own tissue and cells [18, 19].
Over the medium to long term, the resident fibroblasts secrete cytokines and 
growth factors to signal reinforcement of the deposited tissue through the processes 
of additional collagen deposition and maturation, resulting in a strong, repaired tis-
sue [10, 20–22]. In this phase, the biologic graft is no longer needed as the patient’s 
own collagen has gradually matured into a stable structure that has long-term 
strength but is entirely the patient’s own [20–22]. The resulting tissue structure 
is mature, organized and strong, and can withstand (and is even driven by) the 
natural physiological forces that it encounters [17, 23].
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A biologic graft with the correct composition and three-dimensional architec-
ture directs the patient’s body to replace itself – to completely remodel – rather than 
to heal through a tissue repair process that results in chaotic, weak, and ineffective 
scar tissue formation [20–22]. By providing the correct cues to help the body restore 
itself, the graft provides both an essential temporary structure and the local tissue 
instructions to lead the patient to achieve a natural repair (Figure 3).
4. Mechanisms of action for ECM-directed tissue remodeling
An ECM-based biologic graft that has been optimally processed to harness the tis-
sue remodeling properties of nature acts more than just a mechanical tissue reinforce-
ment device. While mechanical reinforcement is still the primary mechanism of action 
Figure 2. 
The phases of wound healing and the processes involved in each stage. The addition of an ECM graft material 
shortly after the injury occurs results in a more natural wound healing response than in its absence.
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for these materials, additional mechanisms of action include: providing a porous tissue 
scaffold matrix structure to allow for fibroblast infiltration and population; altering 
the surrounding wound environment by modulating local cytokine activity; and, 
optimally, acting as a reservoir for growth factors and signaling molecules that can be 
used by the patient as tissue renewal and reinforcement progress (Table 2).
4.1 Mechanical reinforcement during surgical repair
Poor wound healing after trauma, surgery, or due to chronic disease is the 
consequence of a poorly regulated tissue repair response that directly effects the 
processes of inflammation, angiogenesis, matrix deposition, and cell recruitment 
[24]. As a result, tissue healing typically takes a significant time to achieve in 
patients with advanced age or with comorbidities. Prolonged mechanical reinforce-
ment is often needed to get proper approximation of the wound edges and to bolster 
the anatomy until tissue ingrowth is sufficient to achieve the required strength to 
maintain tissue integrity. This mechanical reinforcement mechanism is the primary 
(and often only) means by which most implantable devices achieve their effect. For 
example, synthetic mesh materials, such as polypropylene or polytetrafluoroethyl-
ene, derive their reinforcement benefit from the strength of their fibers at implant 
but never completely integrate with the patient’s tissues over time [25]. Synthetic 
materials are often recognized as foreign by the body – as a material that needs to be 
removed or expunged [26]. When this occurs, an inflammatory response is initiated 
by the patient’s immune system, setting up a chronic inflammatory state that never 
resolves and can result in chronic pain and fibrosis [26].
Figure 3. 
Mechanisms of action for ECM-directed tissue remodeling. The ECM graft initially provides for a direct 
mechanical tissue repair that has inherent strength. It also provides a matrix structure for the support, 
attachment, and orientation of cells. The ECM graft has the ability, through its inherent composition, to 
modulate the local wound environment to have a direct effect on endogenous growth factors and cytokines. 
The graft can provide signals of its own, which may include growth factors, binding sequences on extracellular 
matrix proteins, or other endogenous factors provided by the recipient. Signals control and modify cells and 
other elements. Together the ECM and signals stimulate cell division, proliferation, growth, and integration of 










































Tissue Scaffold Matrix 
Structure
Modulation of Endogenous 
Cytokines
Delivery of Exogenous Cytokines
Synthetic mesh implant
Bio-synthetic mesh implant
Cross-linked ECM biologic graft
Purified ECM biologic graft
Naturally complex ECM biologic 
graft
Table 2. 
Mechanisms of action for different types of implantable graft materials. While all implantable materials serve a mechanical function to reinforce soft tissue, synthetic and biosynthetic materials 
fail to provide a matrix structure and complex composition that is designed to positively interact with the wound healing environment and lead to constructive tissue remodeling that is seen with 
naturally complex ECM biologic graft materials.
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For a well-designed biologic ECM graft, the mechanical means of tissue support 
remains its primary mechanism of action. The ECM graft must allow the passage of 
suture and reinforce the area of weakness under significant pull-out force. It must 
also provide tensile strength and mechanical compliance commensurate with the 
surrounding tissues. Unlike synthetic or even many biosynthetic materials, such as 
poly-4-hydroxybutyrate (P4HB), ECM-based biologic devices are not meant to be 
static implants but are designed to fully integrate with the patient over time. Their 
mechanical properties change after implant as they undergo interaction with the 
patient’s cells, tissues, and the local wound environment [27] and must therefore be 
designed to retain their mechanical integrity even while actively participating in the 
process of tissue renewal. The dynamic process of tissue remodeling is a balance of 
ECM graft degradation with the formation of new patient-derived collagen, meaning 
that an ECM graft must be designed with known strength requirements and degra-
dation rates to keep the repair intact during all phases of tissue remodeling: 1) Cell 
recruitment; 2) Tissue renewal; and 3) Tissue reinforcement (Figure 4) [20, 28].
4.2 Providing a tissue scaffold matrix structure
When foreign materials are implanted into the body, they are quickly recog-
nized by the immune system as something either to rapidly destroy or to compart-
mentalize [29]. The body accomplishes these activities by secreting inflammatory 
enzymes and pH modifiers or by recruiting an army of macrophages to form 
a scarified wall around the implant. While permanent synthetic materials and 
crosslinked biologic grafts are typically walled off by the recipient because they 
are resistant to degradation [30], biosynthetic matrices are often hydrolyzed or 
otherwise degraded over time without allowing complete tissue integration and 
permanent reinforcement to occur [31].
Purified biologic ECM grafts typically contain few of the naturally occurring 
macromolecules of the complex ECM because they have been deconstructed with 
chemicals and then “purified” into single-component constructs or reconstituted 
into single-component implants. While this type of graft material can still act as a 
matrix structure to support cell ingrowth, the lack of complex signaling macromol-
ecules from the natural ECM and its susceptibility to matrix-degrading enzymes, 
such as collagenases, limits its ability to actively promote fibroblast and endothelial 
cell proliferation and secretion of new ECM [32, 33].
Figure 4. 
ECM-based graft materials must be designed to withstand physiologic forces while undergoing the active 
processes of tissue remodeling and tissue integration following implant. The overall repair strength must be 
maintained well above the normal tissue strength required to keep the repair intact while facilitating cell 
recruitment, tissue renewal, and tissue reinforcement.
9
The Interplay of ECM-Based Graft Materials and Mechanisms of Tissue Remodeling
DOI: http://dx.doi.org/10.5772/intechopen.96954
Non-crosslinked biologic ECM grafts that have been processed to retain the 
composition and architecture of healthy ECM are neither encapsulated nor 
degraded upon implant [7]. Instead, they contain the complex information of the 
natural ECM that makes them an ideal scaffold environment upon which cells can 
move and proliferate, allowing for colonization of fibroblasts and endothelial cells, 
the eventual secretion of growth factors, and the deposition of a collagen matrix 
[10]. The porous nature of the ECM scaffold provides not only the structure and 
interstices for ingrowth but also the recognition and binding sites that facilitate 
cellular attachment and migration [10]. During the process of tissue renewal, the 
porous matrix structure of the non-crosslinked ECM graft allows for angiogenesis 
and ultimately the removal of byproducts of cellular metabolism, facilitating the 
process of tissue remodeling that is essential to obtaining a long-lasting, strong, and 
permanent repair [10, 34].
4.3 Modulating endogenous cytokine activity
The local wound environment is characterized by a dynamic milieu of signaling 
factors designed to shepherd an injury through the four phases of wound healing 
and to ultimately restore tissue strength and homeostasis [16]. In most instances 
this occurs in a well-defined series of events leading to complete tissue restoration 
that is modulated directly by the local ECM. Because the ECM is laden with macro-
molecules that explicitly bind cytokines and alter their half-lives, bioactivities, and 
concentrations, the presence of a healthy ECM in the local wound environment is 
essential for tissue remodeling to occur. When the ECM is corrupt, it cannot sup-
port tissue restoration and chronic inflammation results [35].
Chronic, non-healing wounds are characterized by increased levels of pro-
inflammatory cytokines, increased levels of MMPs, and low levels of growth factors 
known to stimulate wound closure [36, 37]. They are highly inflamed and proteo-
lytic, have become stalled in the inflammation stage of wound healing, and cannot 
support fibroblast function [38]. In cases such as this, replacing the damaged ECM 
with a healthy ECM-based biologic graft can alter the local wound environment by 
modulating the endogenous cytokine profile of the injured area and stimulating 
normal fibroblast and endothelial cell function [39].
This tertiary mechanism of action for ECM-directed tissue remodeling, endog-
enous cytokine modulation, harnesses the natural structure and composition of the 
ECM to direct tissue remodeling down a productive pathway [37]. Unlike synthetic 
and biosynthetic materials that contain no ECM-binding sites and cannot directly 
influence the composition of the natural wound environment; unlike crosslinked 
ECM biologic graft materials which have had their binding sites obscured by the 
crosslinking process; and unlike purified biologic ECM grafts that are limited in 
the types of cytokines that can interact with them; well-designed, non-crosslinked, 
biologic ECM graft materials have been shown to positively alter the local environ-
ment and lead to constructive tissue remodeling and wound healing [10, 37, 39, 40].
4.4 Acting as a cytokine reservoir
Matrix biologists have long regarded the ECM as a repository for latent bioactiv-
ity in the form of growth factors, cytokines, and more recently, messenger nucleic 
acid depots. Even in their dehydrated state, these factors retain their potency and 
structure because they are tightly bound to proteins that protect them from deg-
radation [41, 42]. Also, recently, science has uncovered the remarkable ability for 
these embedded matrix molecules to modulate cellular activity across species and 
after long periods of dormancy. Porcine growth factors can activate human cells, 
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and vice-versa, with predictable potency and expected effects, even after dehydra-
tion and sterilization [41, 42]. It is this growth factor and cytokine repository that 
separates a complex biologic ECM graft from other types of non-instructional 
implant materials.
After implantation, a complex biologic ECM graft plays the role of the innate 
ECM, interacting with the patient’s cells through dynamic reciprocity to direct 
tissue repair down a positive, active state of wound healing and toward an orga-
nized repair that resembles native tissue structure and architecture rather than scar 
tissue. When its role has been fully realized, an ECM graft becomes completely 
replaced by patient tissue and removed from the body through the normal process 
of matrix turnover, leaving no graft components behind [43]. In many ways it is the 
repository of latent bioactivity that allows the well-designed ECM graft to stimulate 
transformation of itself, by the patient’s cells, into a new, complex and complete, 
functional tissue.
5. Summary: extracellular matrix past, present, and future
ECM graft materials have been used surgically for decades, but historically 
they have been enzymatically stripped of their biological information, chemically 
cross-linked to enhance their durability (while quite effectively silencing their 
biological activity), or otherwise adulterated in such a way as to act much more like 
synthetic mesh than a truly instructive matrix [34, 44]. A more modern approach 
to ECM graft design can capitalize on the inherent complexity and instructiveness 
of natural ECM to build an implant with multi-factorial mechanisms of action that 
harmonize with healing, serve as a surrogate ECM in the wound, and stimulate the 
processes of dynamic reciprocity toward renewed homeostasis. Such an implant 
can guide the patient’s cells through a series of cellular recruitment, renewal of lost 
matrix structures, and reinforcement of tissue strength while undergoing complete 
turnover and disappearance of the original implant.
The current state of the art for ECM grafts has been described. These  
materials have shown remarkable success in a wide variety of clinical applica-
tions [3, 7]. However, there is still room for improvement. Naturally occurring 
biologic ECM graft materials can be enhanced or fortified to accelerate some of 
these biological functions, stimulate cellular phenotype selection, or even create 
inherent antimicrobial activities that will better withstand infection. Ultimately, 
the goal of such “next generation” implants must be one of synergizing with 
natural biology and improving upon the complex interaction of the graft with 
the patient to allow tissue repair, remodeling, and regenerative processes to 
proceed unhindered.
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